Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07069699 · ClinicalTrials.gov registry record · Phase 1

Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene

A Phase 1 study of Burkitt Lymphoma and High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, sponsored by National Cancer Institute (NCI).

Recruiting
Registry status
Phase 1
Development phase
50
Enrollment target
1
Study location

NCT07069699 is a Phase 1 study of Burkitt Lymphoma and High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 50 participants, below the 74-participant average among 22 other Burkitt Lymphoma trials with a reported enrollment target (32% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07069699, a Phase 1 study of Burkitt Lymphoma and High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, is actively recruiting participants, sponsored by National Cancer Institute (NCI).

RECRUITING
Registry status
Phase 1
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

This phase Ib/II trial tests the safety, side effects, best dose and how well giving CX-5461 works for the treatment of patients with B-cell non-Hodgkin lymphoma. CX-5461 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving CX-5461 may be safe, tolerable and/or effective in treating patients with B-cell non-Hodgkin lymphoma.

Conditions Studied

Burkitt Lymphoma High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements Double-Expressor Lymphoma

Interventions

  • PROCEDURE Biospecimen Collection
  • PROCEDURE Computed Tomography
  • PROCEDURE Lumbar Puncture
  • PROCEDURE Biopsy Procedure
  • DRUG Pidnarulex

Study Locations (1)

Connecticut

  • Yale University Cancer Center LAO - New Haven

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2026-10-13
Est. Completion 2030-01-31
Phase Phase 1

Sponsor

National Cancer Institute (NCI)

3,257 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07069699

The ClinicalTrials.gov registry entry for NCT07069699 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 74-participant average among 22 other Burkitt Lymphoma trials with a reported enrollment target (32% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Burkitt Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT07069699 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.

Frequently Asked Questions

What is clinical trial NCT07069699 about?

NCT07069699 is a clinical study titled "Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene". This phase Ib/II trial tests the safety, side effects, best dose and how well giving CX-5461 works for the treatment of patients with B-cell non-Hodgkin lymphoma. CX-5461 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving CX-5461 may be safe, tolerable...

What is the current status of trial NCT07069699?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2026-10-13. Estimated completion is 2030-01-31.

What conditions does trial NCT07069699 study?

This clinical trial studies the following conditions: Burkitt Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, Double-Expressor Lymphoma.

What interventions are being tested in trial NCT07069699?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Lumbar Puncture (PROCEDURE), Biopsy Procedure (PROCEDURE), Pidnarulex (DRUG).

Who is sponsoring clinical trial NCT07069699?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07069699 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Burkitt Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Burkitt Lymphoma

All registered trials for this condition

High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements

All registered trials for this condition

Connecticut

All trials with a study site in Connecticut

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.